Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05LBU
|
|||
| Former ID |
DAP000723
|
|||
| Drug Name |
Ticlopidine
|
|||
| Synonyms |
Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Stroke [ICD-11: 8B20; ICD-10: I64] | Approved | [1], [2] | |
| Therapeutic Class |
Fibrinolytic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H14ClNS
|
|||
| Canonical SMILES |
C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
|
|||
| InChI |
1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
|
|||
| InChIKey |
PHWBOXQYWZNQIN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 55142-85-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9349, 5650061, 7980793, 8153361, 10526772, 11112786, 11466075, 11467195, 11485830, 15197138, 26751617, 29224517, 46504438, 47291227, 47440368, 47589090, 48110545, 48416628, 49698319, 50053360, 50085878, 50100522, 50139240, 50661300, 57288855, 57322795, 61110231, 85209800, 85787491, 90945105, 92308854, 92714062, 93167187, 93625532, 96025278, 99309316, 103219164, 104171328, 104309332, 117785149, 124882622, 124882623, 124882624, 124882625, 124882626, 124882627, 125203923, 126629679, 126666024, 128918298
|
|||
| ChEBI ID |
CHEBI:9588
|
|||
| ADReCS Drug ID | BADD_D02215 ; BADD_D02216 | |||
| SuperDrug ATC ID |
B01AC05
|
|||
| SuperDrug CAS ID |
cas=055142853
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Platelet-activating factor receptor (PTAFR) | Target Info | Modulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (q) signalling events | ||||
| Interferon gamma signaling | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Interferon gamma signaling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7307). | |||
| REF 2 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.